A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Vinay Prasad to exit FDA again, following latest round of controversy
Vinay Prasad to exit FDA again, following latest round of controversy
Lonza sells capsule and health ingredients unit for $2.2B
Lonza sells capsule and health ingredients unit for $2.2B
Lonza sells capsule and health ingredients unit to UK's Lone Star for $2.2B - Endpoints News
Lonza sells capsule and health ingredients unit to UK's Lone Star for $2.2B - Endpoints News
Servier to buy Day One for $2.5B, gaining rare oncology medicines
Servier to buy Day One for $2.5B, gaining rare oncology medicines
Solid Biosciences gets $240M for pipeline; Roche expounds on lupus data
Solid Biosciences gets $240M for pipeline; Roche expounds on lupus data
Post-Hoc Live: What will the US government do about China biotech?
Post-Hoc Live: What will the US government do about China biotech?
Pfizer gets obesity drug approval in China shortly after buying local rights
Pfizer gets obesity drug approval in China shortly after buying local rights
Lilly plucks Flagship, bluebird vet for regenerative medicine unit; Novo's new China president
Lilly plucks Flagship, bluebird vet for regenerative medicine unit; Novo's new China president
FDA official questions need for advisory committees
FDA official questions need for advisory committees
Kura says its menin inhibitor is preferred treatment for some payers
Kura says its menin inhibitor is preferred treatment for some payers
Roche partner Zealand posts Phase 2 data for amylin obesity drug
Roche partner Zealand posts Phase 2 data for amylin obesity drug
Roche, Element and Ultima push toward the $100 genome
Roche, Element and Ultima push toward the $100 genome
FDA approves J&J's multiple myeloma combo as second-line treatment
FDA approves J&J's multiple myeloma combo as second-line treatment
Helus Pharma's stock slides after psychedelic drug data face questions over dosing
Helus Pharma's stock slides after psychedelic drug data face questions over dosing
New FDA bonus pilot to address 'workforce challenges'
New FDA bonus pilot to address 'workforce challenges'
Eli Lilly's new program aims to boost employer coverage of GLP-1s
Eli Lilly's new program aims to boost employer coverage of GLP-1s
Tenaya wins support from Alnylam in cardio disease pact
Tenaya wins support from Alnylam in cardio disease pact
Health AI dispatch from SF
Health AI dispatch from SF
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page